Overview

Evaluating the Abuse Potential of Neurontin® When Taken Orally in Healthy Non-drug Dependent Participants With Sedative Drug Abuse Experience

Status:
Not yet recruiting

Trial end date:
2021-06-01

Target enrollment:

Participant gender:

Summary

This will be a randomized, double-blind, double-dummy, placebo- and active controlled, 5 treatment, 10 sequence, 5 period crossover single dose, Williams square design study in healthy adult, non drug dependent male and female participants with drug abuse experience with sedative drugs.

Phase:

Phase 4

Details

Lead Sponsor:

Pfizer

Treatments:

Diazepam
Gabapentin